Machine learning-based approach to guide the choice between baricitinib and tocilizumab in critical COVID-19 pneumonia treatment: a retrospective cohort study.
Saved in:
| Title: | Machine learning-based approach to guide the choice between baricitinib and tocilizumab in critical COVID-19 pneumonia treatment: a retrospective cohort study. |
|---|---|
| Authors: | Chang E; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Kim MS; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.; ImpriMedKorea, Inc., Seoul, Republic of Korea., Park SY; Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea., Kwon K; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Jang HM; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Lim SY; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Bae S; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Jung J; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Kim MJ; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Chong YP; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Lee SO; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Choi SH; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Kim YS; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Choi G; ImpriMedKorea, Inc., Seoul, Republic of Korea., Lim S; ImpriMed, Inc., Mountain View, CA, United States., Koo J; ImpriMedKorea, Inc., Seoul, Republic of Korea.; ImpriMed, Inc., Mountain View, CA, United States.; Department of Chemical Engineering, Hongik University, Seoul, Republic of Korea., Kim SH; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. |
| Source: | Frontiers in medicine [Front Med (Lausanne)] 2026 Jan 07; Vol. 12, pp. 1734109. Date of Electronic Publication: 2026 Jan 07 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101648047 Publication Model: eCollection Cited Medium: Print ISSN: 2296-858X (Print) Linking ISSN: 2296858X NLM ISO Abbreviation: Front Med (Lausanne) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2296-858X |
|---|---|
| DOI: | 10.3389/fmed.2025.1734109 |
